Cancer Discov. 2016 Apr;6(4):338. doi: 10.1158/2159-8290.CD-ND2016-002. Epub 2016 Mar 9.
Researchers in the adoptive T-cell therapy field are continuing to refine the ways in which the specificity of these immune cells can be redirected toward tumors. They've found that selecting the most persistent, proliferative T cells-and genetically manipulating only these defined subsets-ensures a potent therapeutic product that's effective even at minuscule doses.
在过继性 T 细胞疗法领域，研究人员正在不断改进这些免疫细胞特异性识别肿瘤的方法。他们发现，选择最持久、增殖能力最强的 T 细胞，并对这些特定亚群进行基因修饰，可确保获得有效的治疗产品，即使在微小剂量下也能发挥作用。
